CAS NO: | 914088-09-8 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
生物活性 | Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate(ADC)comprising an anti-CD30antibody and the cytotoxic agent MonomethylauristatinE (MMAE). Brentuximab vedotin inhibitsCD30-positive cells with anIC50of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma[1][2]. | ||||||||||||||||
IC50& Target | IC50: 2.5 ng/mL (CD30)[2] | ||||||||||||||||
体外研究 (In Vitro) | Brentuximab vedotin (cAC10-vcMMAE) (1 μg/mL; 96 h) shows cytotoxicity to CD30+in Karpas 299 cells[2].Brentuximab vedotin (CAC10-VCMMAE) (1 μg/mL; 12, 24 and 48 h) selectively induces growth arrest in G2/M phase then lead to apoptotic cell death[2]. Cell Cytotoxicity Assay[2]
Cell Cycle Analysis[2]
| ||||||||||||||||
体内研究 (In Vivo) | Brentuximab vedotin (cAC10-vcMMAE) (10-120 mg/kg; i.p. for 3 weeks) the maximum tolerated dose (MTD) is between 30 and 40 mg/kg[2].Brentuximab vedotin (cAC10-vcMMAE) (0.3, 1 mg/kg; flanks injection; every 4 days for a total of 4 doses 1 mg/kg) induces tumor CD30 regression[2].
| ||||||||||||||||
Clinical Trial | |||||||||||||||||
性状 | Solid | ||||||||||||||||
CAS 号 | 914088-09-8 | ||||||||||||||||
中文名称 | 维布妥昔单抗;本妥昔单抗 | ||||||||||||||||
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |